# AvertD Post-Approval Study

> **NCT07135323** · — · RECRUITING · sponsor: **Prescient Medicine Holdings, Inc.** · enrollment: 4000 (estimated)

## Conditions studied

- Opioid Use Disorder

## Interventions

- **GENETIC:** Opioid Used Disorder Risk Assessment

## Key facts

- **NCT ID:** NCT07135323
- **Lead sponsor:** Prescient Medicine Holdings, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-15
- **Primary completion:** 2031-11
- **Final completion:** 2031-11
- **Target enrollment:** 4000 (ESTIMATED)
- **Last updated:** 2025-08-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07135323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07135323, "AvertD Post-Approval Study". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT07135323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*